SILVERARC CAPITAL MANAGEMENT, LLC

Position in ASND — Ascendis Pharma A/S

CIK 1816307 BOSTON, MA

Position in ASND

as of Mar 31, 2026 · filed May 14, 2026 Compact

Position Value

$28,513,024

+$18,015,646 QoQ

Shares Held

124,658

+153.2% QoQ

Ownership

0.190%

of shares outstanding

% of Portfolio

3.37%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2020

13 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

SILVERARC CAPITAL MANAGEMENT, LLC holds $782,503,784 across 55 Biotechnology names. ASND ranks #11 (3.6% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	KALV	KalVista Pharmaceuticals, Inc.	2,876,407	$57,902,072
2	DNTH	Dianthus Therapeutics, Inc. /DE/	654,746	$54,946,284
3	COGT	Cogent Biosciences, Inc.	1,314,189	$50,583,134
4	CELC	Celcuity Inc.	357,903	$40,851,048
5	IMNM	Immunome Inc.	1,850,278	$40,465,579
6	KOD	Kodiak Sciences Inc.	991,930	$37,812,371
7	NUVL	Nuvalent, Inc.	354,914	$36,360,939
8	ABVX	Abivax S.A.	302,530	$33,686,715

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$28,513,024	124,658	+153.2%	Shares	Sole	2026-05-14
2025-12-31	$10,497,378	49,228	-8.1%	Shares	Sole	2026-02-12
2025-09-30	$10,647,070	53,554	-38.1%	Shares	Sole	2025-11-12
2025-06-30	$14,938,875	86,552	+14.3%	Shares	Sole	2025-08-14
2025-03-31	$11,806,550	75,751	+47.1%	Shares	Sole	2025-05-14
2024-12-31	$7,088,765	51,491	+929.8%	Shares	Sole	2025-02-14
2024-09-30	$746,550	5,000	-78.4%	Shares	Sole	2024-11-14
2022-12-31	$2,827,431	23,151	+363.0%	Shares	Sole	2023-02-14
2022-09-30	$516,300	5,000	-80.0%	Shares	Sole	2022-10-28
2022-03-31	$2,934,000	25,000	+346.5%	Shares	Sole	2022-05-13
2021-06-30	$736,548	5,599	-70.0%	Shares	Sole	2021-08-16
2021-03-31	$2,409,282	18,694	+6.5%	Shares	Sole	2021-05-18
2020-12-31	$2,927,989	17,556	—	Shares	Sole	2021-02-16
No filing history on record for this holder in this stock.